Joshua J. Meeks, MD, PHD (he/him/his)

Associate Professor of Urology, Biochemistry and Molecular Genetics
Northwestern University

Joshua Meeks, MD, PhD is an Associate Professor of Urology, Biochemistry and Molecular Genetics at Northwestern Univeristy. His research laboratory is focused on the molecular pathways involved in the progression of urothelial carcinoma. Dr. Meeks's research has two themes: 1) to investigate the epigenetic mechanisms of gene regulation in bladder cancer and 2) to identify the interaction of the immune response to tumor mutations. Dr. Meeks has a clinical trial study of intravesical immunotherapy for BCG-refractory bladder cancer at Northwestern and is the bladder-site translational medicine chair for the SouthWest Oncology (SWOG) GU Committee. Dr. Meeks specializes in the surgical treatment of non-muscle and muscle-invasive bladder cancer with an emphasis on novel therapeutics for bladder cancer.

Disclosure information not submitted.

Presentation(s):

• How the Experts Treat NMIBC During A BCG-Shortage Integrating Recent Approvals and Investigational Therapies

  Friday, April 28, 2023
  8:00 AM – 10:00 AM CST

• Bladder Cancer Omics Data: Investigating Mechanisms of Immune Response

  Saturday, April 29, 2023
  9:35 AM – 10:05 AM CST

• Beyond the Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Bladder Cancer

  Sunday, April 30, 2023
  7:30 AM – 10:00 AM CST

• Optimizing BCG Therapy/Managing BCG Toxicity

  Sunday, April 30, 2023
  3:50 PM – 4:10 PM CST